ArticleEcancermedicalscience2026
Trends in cancer burden in Pakistan: a 30-year analysis from the Global Burden of Disease Study (1990-2019).
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of pricing, availability, and affordability of essential medicines in a resource-limited setting.Journal of pharmaceutical policy and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is a leading cause of mortality worldwide, with significant regional disparities in its burden. In Pakistan, the sixth most populous country, cancer contributes significantly to the healthcare burden, yet comprehensive epidemiological studies are limited. Methods: A population-based analysis was conducted using Global Burden of Disease (GBD) 2019 data. Cancer metrics, including incidence, mortality and disability-adjusted life years (DALYs), were extracted and stratified by age, gender, cancer type and geographic region. Annual average percent changes (AAPCs) were calculated to evaluate temporal trends. This study aimed to analyse trends in cancer incidence, mortality and DALYs in Pakistan from 1990 to 2019, using data from the GBD study. Results: Total cancer incidence increased from 1.28 million cases (1990) to 2.77 million cases (2019), with an annual average percent change (AAPC) of 0.11%. Mortality rose from 73,424 deaths (age-standardised rate (ASR): 122.16) to 179,773 deaths (ASR: 153.52) (AAPC: 0.79%) and DALYs increased from 2.41 million (ASR: 3,363.75) to 6.27 million (ASR: 3,439.9) (AAPC: 0.85%). Breast cancer remained the leading contributor to the disease burden, accounting for 51,438 cases, 32,118 deaths and 1.12 million DALYs in 2019. Pancreatic cancer showed the highest growth in incidence (AAPC: 3.39%), while ovarian cancer exhibited the largest increases in mortality (AAPC: 3.16%) and DALYs (AAPC: 5.85%). Punjab reported the highest burden, with 1.49 million cases in 2019. Female cancer incidence and mortality consistently exceeded male figures, with an AAPC of 0.15% in incidence and 1.07% in mortality. Age-specific analyses revealed that leukaemia was the leading cancer in children aged 0-14, while lung cancer dominated among males over 50 years. Conclusion: The rising cancer burden in Pakistan underscores the need for a robust, nationwide cancer registry and targeted interventions. Public health policies must address risk factors such as smoking, hepatitis infections and socio-economic disparities to curb this escalating crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.